Interstitial lung disease guideline

Wells, Adrian; Hirani, Nikhil

doi:10.1136/thx.2008.101691

Cited by 595 publications

(235 citation statements)

References 685 publications

(645 reference statements)

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…Evidence-based therapy for IPF is lacking. For example, the 2008 BTS statement on ILDs only weakly recommends one therapy for IPF [3].…”

Section: Introductionmentioning

confidence: 99%

“…Preferably, a consensus diagnosis is then made between clinician, radiologist and pathologist. A diagnosis reached in this multidisciplinary setting currently often serves as the 'gold standard' [3]. However, the clinical setting of this diagnostic process influences the outcome significantly, and even between experienced radiologists and pathologists there is considerable inter-observer variation, invariably implying a diagnostic uncertainty [6][7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum biomarkers in idiopathic pulmonary fibrosis

Blink

Wijsenbeek

Hoogsteden

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…Evidence-based therapy for IPF is lacking. For example, the 2008 BTS statement on ILDs only weakly recommends one therapy for IPF [3].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum biomarkers in idiopathic pulmonary fibrosis

Blink

Wijsenbeek

Hoogsteden

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…The recommendations are based on up-to-date literature data and take into account aspects included in current recommendations compiled by other scientific societies including the European Dermatology Forum guidelines [3,46] co-created by Polish dermatologists, recommendations issued by EULAR Scleroderma Trial and Research Group [1], co-created by Polish rheumatologists, as well as recommendations released in the UK [26], USA and Canada [41], and Australia and New Zealand [47].…”

Section: Discussionmentioning

confidence: 99%

“…podsuMoWAnie Niniejsze rekomendacje są oparte na współczes-nych danych z piśmiennictwa i uwzględniają elementy aktualnych rekomendacji innych towarzystw naukowych, w tym współtworzonych przez polskich dermatologów rekomendacji European Dermatology Forum [3,46], współtworzonych przez polskich reumatologów zaleceń EULAR Scleroderma Trial and Research Group [1], zaleceń brytyjskich [26], amerykańskich i kanadyjskich [41], australijskich i nowozelandzkich [47].…”

Section: Conflict Of Interestunclassified

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment

Krasowska¹,

Rudnicka²,

Dańczak‐Pazdrowska³

et al. 2017

View full text Add to dashboard Cite

Systemic sclerosis is an immune-mediated disease characterized by a chronic progressive course. The complex and diverse clinical features seen in patients require case-by-case approach and cooperation of multiple specialists both at the stage of diagnosis and treatment. Critical factors in systemic sclerosis include early diagnosis, assessment of internal organ involvement, identification of patients at potential risk of organ complications, assessment of disease dynamics and activity, and implementation of optimal therapy. Treatment decisions should be made individually for each patient after careful consideration of such aspects as the severity of skin lesions, duration and activity of the disease, manifestations and possible internal organ involvement. On account of potential organ dysfunctions, patients require a multidisciplinary therapeutic approach and coordinated treatment by experienced specialists or in specialist medical centres. Part 2 presents current guidelines for the treatment of systemic sclerosis. pracy wielospecjalistycznej zarówno na etapie diagnozowania, jak i leczenia. W twardzinie układowej ważne są wczesne rozpoznanie, ocena zajęcia procesem chorobowym narządów wewnętrznych, identyfikacja chorych z ryzykiem wystąpienia powikłań narządowych, ocena dynamiki i aktywności choroby i wdrożenie optymalnej terapii. Decyzja o leczeniu powinna być podejmowana indywidualnie dla każdego pacjenta po wnikliwej analizie nasilenia zmian skórnych, czasu trwania, oceny aktywności choroby oraz występujących dolegliwości i zmian w narządach wewnętrznych. Ze względu na potencjalne dysfunkcje narządowe pacjent wymaga wielodyscyplinarnego podejścia terapeutycznego i koordynowania leczenia przez doświadczonych specjalistów lub w ośrodkach specjalistycznych. W części drugiej przedstawiono aktualne rekomendacje dotyczące leczenia.

show abstract

“…The rehabilitation programme is recommended in ILD as well, although the recommendation lacks the quality of evidence (Wells & Hirani, 2008) as the effect of the rehabilitation programme has been briefly studied in such population. As a consequence, ILD patients are less likely to be referred to attend the rehabilitation programme.…”

Section: Introductionmentioning

confidence: 99%

An effect of the outpatient rehabilitation programme in patients with chronic respiratory diseases

Zatloukal¹,

Neumannová²,

Olšáková³

et al. 2013

Acta Gymnica

View full text Add to dashboard Cite

BACKGROUND: Pulmonary rehabilitation is a common type of complex treatment especially in patients with chronic obstructive pulmonary disease (COPD). By contrast, only few rehabilitation centres in the Czech Republic provide pulmonary rehabilitation programme to non-COPD patients. OBJECTIVE: To find out if the rehabilitation programme has a similar effect in patient with obstructive and restrictive ventilatory disorder. METHODS: Twenty-eight patients with either COPD or pulmonary sarcoidosis (PS) have been enrolled for the 6-week rehabilitation programme. Lung functions, maximal inspiratory (MIP) and expiratory (MEP) mouth pressures, chest expansion at the level of the 4th intercostal space (IC) and at the level of the xiphoid process (XP), sixminute walk test, health-related quality of life using the St. George's Questionnaire (SGRQ) and fatigue occurrence using the Multidimensional Assessment of Fatigue scale (MAF) were tested at the baseline and after 6 weeks. The rehabilitation programme consisted of exercise training, ventilatory muscle training, respiratory physiotherapy and soft-tissue techniques. RESULTS: Patients with COPD improved significantly (p < .05) in MIP by 17% (10.5 cm H 2 O), MEP by 18% (16.8 cm H 2 O), IC by 65% (1.7 cm), XP by 90% (1.9 cm), six-minute walk distance (6MWD) by 15% (64.1 m) and SGRQ by -28% (-12.3 points). Patients with PS improved significantly (p < .05) in MIP by 25% (20.1 cm H 2 O), IC by 29% (1.3 cm), XP by 29% (1.3 cm) and 6MWD by 6% (31.6 m). The change in lung functions and MAF in both groups; MEP and SGRQ in PS group were insignificant after the 6-week rehabilitation programme. CONCLUSIONS: The 6-week rehabilitation programme produces similar responses in functional health status of patients with either obstructive or restrictive ventilatory disorder. However, patients with restrictive ventilatory disorder in particular should be encouraged to continue in the programme to enhance the health-related quality of life, which might not be sufficiently affected after 6 weeks.

show abstract

Interstitial lung disease guideline

Cited by 595 publications

References 685 publications

Serum biomarkers in idiopathic pulmonary fibrosis

Serum biomarkers in idiopathic pulmonary fibrosis

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment

An effect of the outpatient rehabilitation programme in patients with chronic respiratory diseases

Contact Info

Product

Resources

About